Weave Communications, Inc. (DUSE:7OP)
Germany · Delayed Price · Currency is EUR | Market Cap | 531.54M +19.2% |
| Revenue (ttm) | 225.64M +16.7% |
| Net Income | -17.98M |
| EPS | -0.23 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 35.61 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 6.45 |
| Previous Close | 6.50 |
| Day's Range | 6.45 - 6.55 |
| 52-Week Range | 6.29 - 6.55 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Oct 28, 2026 |
About Weave Communications
Weave Communications, Inc. operates an AI-powered patient communications, engagement, and payments platform for small and medium-sized healthcare businesses. It offers AI-receptionist; Unified Phone Number; Customized Phone System, a smarter phone system to identify whether incoming calls are from new or current patients, provide information at every call, and manage heavy call times; Softphones to make and receive calls from anywhere with an internet connection; Text Messaging and SMS response assistant; Missed Call Text that allows practices ... [Read more]
Financial Performance
In 2025, Weave Communications's revenue was $239.02 million, an increase of 16.99% compared to the previous year's $204.31 million. Losses were -$28.05 million, -1.04% less than in 2024.
Financial numbers in USD Financial StatementsNews
Weave Communications Proxy statement: Proxy filing
Weave Communications filed a proxy statement on October 13, 2026, providing details for shareholder voting and corporate governance matters.
Weave announces live availability of integration with CareCredit
Weave (WEAV) announced the live availability of its integration with CareCredit, a leading patient financing solution from Synchrony (SYF). The integration gives front-office staff real-time visibilit...
Weave and CareCredit Go Live with Integration That Places Patient Financing Inside the Front-Office Workflow
LEHI, Utah--(BUSINESS WIRE)-- #getweave--Weave (NYSE: WEAV), a leading AI-powered patient communications and payments platform purpose-built for healthcare practices, today announced the live availabi...
Weave Communications Proxy statement: Proxy filing
Weave Communications filed a proxy statement on September 25, 2026, providing details for shareholder voting and corporate governance matters.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Personalis, Inc. (Nasdaq – PSNL)
BALA CYNWYD, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (...
Weave Communications Proxy statement: Proxy filing
Weave Communications filed a proxy statement on September 21, 2026, providing details for shareholder voting and corporate governance matters.
Weave Ranks No. 1 in G2's Fall 2026 Patient Relationship Management Grid Report
LEHI, Utah--(BUSINESS WIRE)-- #getweave--Weave (NYSE: WEAV), a leading AI-powered patient engagement and payments platform purpose-built for healthcare practices, has been named the No. 1 Leader in G2...
Weave Communications Proxy statement: Proxy filing
Weave Communications filed a proxy statement on September 15, 2026, providing details for shareholder voting and corporate governance matters.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Centerspace (NYSE – CSR), Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Bio-Techne Corporation (Nasdaq – TECH)
BALA CYNWYD, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (...
Weave Bio Announces Collaboration with Takeda to Deploy AI-Native Regulatory Automation Across Key Drug Development Activities
SAN FRANCISCO--(BUSINESS WIRE)-- #AI--Weave Bio, the leader in AI-native regulatory automation for drug development, today announced a collaboration with Takeda to deploy the Weave platform across 14 ...
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fulcrum Therapeutics, Inc. (Nasdaq – FULC), Weave Communications, Inc. (NYSE – WEAV), Iridium Communications Inc. (Nasdaq – IRDM), Bio-Techne Corporation (Nasdaq – TECH)
BALA CYNWYD, Pa., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (j...
Weave downgraded to Market Perform from Outperform at Raymond James
Raymond James downgraded Weave (WEAV) to Market Perform from Outperform without a price target after the company entered into an agreement to be acquired by Francisco Partners for $650M or…
Weave's 2026 Pulse Survey Finds Healthcare Practices Are Ready for AI, but 60% Are Still Concerned About Data Privacy
LEHI, Utah--(BUSINESS WIRE)-- #getweave--Weave (NYSE: WEAV), a leading AI-powered patient engagement and payments platform purpose-built for healthcare practices, today released its 2026 State of Heal...
Halper Sadeh LLC is Investigating Whether WEAV and FULC are Obtaining Fair Deals for their Shareholders
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
Weave downgraded to Neutral from Buy at B. Riley
B. Riley downgraded Weave (WEAV) to Neutral from Buy with a price target of $7.40, down from $8.25, after the company entered into an agreement to be acquired by Francisco…
Weave Communications Proxy statement: Proxy filing
Weave Communications filed a proxy statement on August 19, 2026, providing details for shareholder voting and corporate governance matters.
Weave downgraded to Hold from Buy at Loop Capital
Loop Capital analyst Mark Schappel downgraded Weave (WEAV) to Hold from Buy with a price target of $7.40, down from $8, after the company entered into an agreement to be…
Weave downgraded to Neutral from Overweight at Piper Sandler
Piper Sandler analyst Hannah Rudoff downgraded Weave (WEAV) to Neutral from Overweight with a price target of $7.40, down from $8, after the company entered into an agreement to be…
Weave downgraded to Hold from Buy at Stifel
Stifel downgraded Weave (WEAV) to Hold from Buy with a price target of $7.40, down from $8, after the company entered into an agreement to be acquired by Francisco Partners…
Weave Communications trading resumes
09:11 EDT Weave (WEAV) Communications trading resumes
Francisco Partners to acquire Weave for $7.40 per share in cash
Weave (WEAV) Communications and Francisco Partners announced that FP has entered into a definitive agreement to acquire Weave, at an aggregate equity valuation of approximately $650M. Under the terms ...
Weave initiated with a Buy at B. Riley
B. Riley analyst Josh Nichols initiated coverage of Weave (WEAV) with a Buy rating and $8.25 price target Weave offers an attractive risk/reward profile, with durable 13%-15% growth, improving margins...
Weave Announces Acquisition by Francisco Partners
LEHI, Utah & SAN FRANCISCO--(BUSINESS WIRE)-- #getweave--Weave Communications, Inc. (“Weave”) (NYSE: WEAV), a leading AI-powered patient engagement and payments platform purpose-built for healthcare p...
Weave Communications trading halted, news pending
08:44 EDT Weave (WEAV) Communications trading halted, news pending
Weave initiated with a Buy at B. Riley
B. Riley initiated coverage of Weave (WEAV) with a Buy rating and $8.25 price target